A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer).

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

SHORT TERM INTENSIFIED PEMBROLIZUMAB (KEYTRUDA) AND TIVOZANIB FOR HIGH-RISK RENAL CELL CARCINOMA - STRIKE

PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PATIENTS WITH METASTATIC HER-2+ BREAST CANCER AT RISK OF CARDIAC TOXICITY

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIAL

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease

MyeloMATCH MASTER SCREENING AND REASSESSMENT PROTOCOL (MSRP) FOR TIER ADVANCEMENT IN THE NCI MYELOMATCH CLINICAL TRIALS

A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX